

U.S. NUCLEAR REGULATORY COMMISSION

MATERIALS LICENSE

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 39, 40, and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

Licensee 1. Valley Health System 2. P.O. Box 3340 1840 Amherst Street Winchester, Virginia 22604-2540	In accordance with the letters dated January 4 and 24, 2009, 3. License number 45-01589-01 is amended in its entirety to read as follows: 4. Expiration date March 31, 2014 5. Docket No. 03003308 Reference No.	
6. Byproduct, source, and/or special nuclear material A. Any byproduct material permitted by 10 CFR 35.100 B. Any byproduct material permitted by 10 CFR 35.200 C. Any byproduct material permitted by 10 CFR 35.300 D. Any byproduct material permitted by 10 CFR 35.400 E. Yttrium 90 F. Iodine 125	7. Chemical and/or physical form A. Any B. Any C. Any D. Sealed Sources (AEA Technology Model CDC.T1, 3M Health Physics Model 6500 Series, Isotope Products Laboratories Model 67-6500 Series) E. Any F. Liquid Iotrex as part of the GliaSite RTS System	8. Maximum amount that licensee may possess at any one time under this license A. As needed B. As needed C. 1000 millicuries D. 1200 millicuries E. 110 millicuries F. 8 curies
9. Authorized use: A. Any uptake, dilution and excretion study permitted by 10 CFR 35.100. B. Any imaging and localization study permitted by 10 CFR 35.200. C. Any diagnostic study or therapy procedure permitted by 10 CFR 35.300. D. Any manual brachytherapy procedure permitted by 10 CFR 35.400. E. For calibration of the licensee's instruments. F. For brachytherapy use in the Proxima Therapeutics' GliaSite Radiotherapy System.		

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**License Number
45-01589-01Docket or Reference Number
03003308

Amendment No. 91

CONDITIONS

10. Licensed material may be used or stored only at the licensee's facilities located at Winchester Medical Center, 1840 Amherst Street, Winchester, Virginia; Shenandoah Valley Cancer Center, 1870 Amherst Street, Winchester, Virginia; and Winchester Medical Center, 300 Campus Boulevard, Winchester, Virginia.
11. The Radiation Safety Officer for this license is Dana Hare, M.S.
12. Licensed material is only authorized for use by, or under the supervision of:
- A. Individuals permitted to work as an authorized user in accordance with 10 CFR 35.13 and 35.14.
- B. The following individuals are authorized users for medical use as indicated:

Authorized UsersMaterial and Use

Norman J. Smith, M.D.

35.400; Iodine 125 for use in the GliaSite RTS System

Margaret Toxopeus, M.D.

35.100; 35.200; 35.300; 35.400

John L. Wood, M.D.

35.100; 35.200; 35.300

Frederic T. Farra, M.D.

35.200

James Dixon Brown, M.D.

35.200

Philip J. O'Donnell, M.D.

35.200

David Kent Harry, M.D.

35.100; 35.200

Karen Straus, M.D.

35.400; Iodine 125 for use in the GliaSite RTS System

Francis W. Willi, M.D.

35.100; 35.200

Blake Howard Watts, M.D.

35.100; 35.200; 35.300

Robert J. Foust, M.D.

35.100; 35.200

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**License Number
45-01589-01Docket or Reference Number
03003308

Amendment No. 91

Authorized UsersMaterial and Use

Bruce L. Flax, M.D.	35.400; Iodine 125 for use in the GliaSite RTS System
Ronald G. Repasky, M.D.	35.100; 35.200
Ayay Virmani, M.D.	35.200
David Snow, M.D.	35.100; 35.200
John C. Hardy, M.D.	35.200
Joseph W. Poe, M.D.	35.100; 35.200; 35.300
David E. Magarik, M.D.	35.200
Curtis J. Thwing, M.D.	35.100; 35.200; 35.300
Edward Bonyak, M.D.	35.200
Trisha B. Nashed, M.D.	35.200
Kyle Wilson Young, M.D.	35.100; 35.200
Preston Stuart Fox, M.D.	35.100; 35.200
Dorthe Sophie Brandt, M.D.	35.100; 35.200
Jason T. Call, M.D.	35.100; 35.200
Daniel Reese, M.D.	35.200
Jeffrey Skiles, M.D.	35.200
Richard Rizzo, M.D.	35.100; 35.200

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**License Number
45-01589-01Docket or Reference Number
03003308

Amendment No. 91

Authorized UsersMaterial and Use

Ather Anis, M.D.

35.200

Manish Lakhani, M.D.

35.200

James R. Sluss, M.D.

35.100; 35.200

Juan Pittaluga, M.D.

35.200

C. The following individuals are authorized users for non-medical uses as indicated:

UsersMaterial and Use

Dana Hare, M.S.

Yttrium 90 for calibration of instruments

Maurice R. Keeler

Yttrium 90 for calibration of instruments

13. In addition to the possession limits in Item 8, the licensee shall further restrict the possession of licensed material to quantities below the minimum limit specified in 10 CFR 30.35(d) for establishing decommissioning financial assurance.
14. The licensee is authorized to transport licensed material in accordance with the provisions of 10 CFR Part 71, "Packaging and Transportation of Radioactive Material."

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**License Number
45-01589-01Docket or Reference Number
03003308

Amendment No. 91

15. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.

- A. Application dated October 22, 2003 (ML032970404)
- B. Letter dated April 26, 2004 (ML041240112)
- C. Letter dated January 24, 2009 (ML090550086)



For the U.S. Nuclear Regulatory Commission

Date March 9, 2009

By **Original signed by Penny Lanzisera**
Penny Lanzisera
Medical Branch
Division of Nuclear Materials Safety
Region I
King of Prussia, Pennsylvania 19406